WEST BRIDGEWATER, Mass.--(BUSINESS WIRE)--Pressure BioSciences, Inc. (NASDAQ: PBIO - News) today announced that it has sold a Pressure Cycling Technology (PCT) Sample Preparation System (PCT SPS) to the Centers for Disease Control and Prevention (CDC), one of 13 major operating components of the Department of Health and Human Services (HHS). HHS is the principal agency in the United States government charged with protecting the health and safety of all Americans and for providing essential human services, especially for those people who are least able to help themselves.
Scientists at the CDC are expected to use the PCT SPS for a variety of research applications, including the extraction of proteins from influenza virus; from bacterial agents such as Clostridium botulinum and Cryptosporidium parasites; and from tissues from laboratory animals that have been exposed to bioterrorism agents, such as anthrax.
Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, commented: "An integral part of our 2006 marketing plan was to install the PCT Sample Preparation System at leading US laboratories that focused on forensics, counter-bioterrorism, agriculture, food safety, infectious diseases, and basic genomic and proteomic research, with the goal of establishing PCT as a crucial part of sample preparation for a wide range of research applications. The installation of the PCT SPS at the CDC represents yet another important achievement in this plan, as we have now sold or leased PCT Systems to the FBI, FDA, NIH, USDA, and CDC, as well as Johns Hopkins University, DermTech Corporation, Veritas Corporation, and the University of New Hampshire."
Schumacher continued: "We enter 2007 with great optimism about our future. In addition to the installations already discussed, we have on-going collaborations with about a dozen other groups who are seriously evaluating the use of the PCT SPS for applications relating to cancer, heart disease, diabetes, bio-marker discovery, and pathogen inactivation. Publications and presentations by independent investigators describing the scientific merits of PCT are beginning to be presented in scientific meetings and published in peer-reviewed journals. We expect to receive 20 new Barocycler NEP3229 instruments between mid-January and the end of March (see April 2006 press release); these instruments will be available for sale upon arrival. We are currently following up on a number of inquiries from scientists, both in the US and abroad, who believe that their research programs might be improved with the addition of Pressure Cycling Technology. Our internal R&D department continues to make progress on the generation of data for additional PCT applications, and our Engineering department continues to make measured progress on the development of new and improved PCT instrumentation and processing tubes. We are looking forward to a busy and exciting 2007."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the CDC's expected use of the PCT SPS, the Company's goal of establishing PCT for a wide range of research applications, the Company's expectations regarding future scientific publications and presentations and the completion of new PCT SPS instruments and processing tubes, and the Company's continued progress in the development of PCT. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT SPS; the possibility that the Company's and the CDC's experiments may not demonstrate an effective use of PCT in the extraction of proteins from samples; the possibility that the Company's PCT technology may not be accepted by the scientific or commercial market as a method for use in infectious diseases and counter-bioterrorism studies, or other applications; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006; in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005; and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Pressure BioSciences, Inc.
Richard T. Schumacher, President & CEO
Edward H. Myles, Vice President of Finance & CFO
Source: Pressure BioSciences, Inc.
>>> Discuss This Story